Atara Biotherap

Q2 FY2026 EarningsQ2 FY2026 results showed a top-line beat but a significant bottom-line miss as the company transition to a skeletal operating model. Revenue of $0.63M exceeded the $0.37M consensus, while GAAP EPS of -$0.32 missed the -$0.26 expectation due to higher-than-anticipated restructuring and administrative costs. The company executed a massive 23% workforce reduction in June 2026, leaving only approximately 10 essential employees. With a going concern warning and a Second Complete Response Letter (CRL) from the FDA for tab-cel, the path to U.S. commercialization remains highly uncertain despite recent alignment on a potential BLA resubmission strategy.